Xencor (XNCR) Is Up 7.1% After Ultomiris Royalty Patent Extension - What's Changed

• Xencor, Inc. recently announced that the U.S. Patent and Trademark Office issued U.S. Patent 12,492,253, extending protection for its Xtend Fc domain used to prolong the half-life of antibodies targeting C5 through December 2028.
• This extension lengthens the U.S. royalty term for Ultomiris by around three years, enhancing visibility on a key royalty stream that Xencor expects will help fund its internal pipeline and innovation efforts.
• We’ll now examine how the extended Ultomiris royalty horizon could reshape Xencor’s investment narrative and its path to funding innovation.

This technology could replace computers: discover 28 stocks that are working to make quantum computing a reality.

Xencor Investment Narrative Recap

To own Xencor, you need to believe its antibody engineering platforms can convert into meaningful, durable royalties and eventually products, despite continued operating losses and competitive TL1A pressure. The Ultomiris royalty extension modestly improves near term funding visibility but does not remove the key risk that late stage development and potential commercialization could remain capital intensive and expose shareholders to further dilution or margin pressure.

The recent Phase 1 data update for XmAb819 in advanced renal cell carcinoma is particularly relevant here, as it highlights Xencor’s effort to broaden its clinical pipeline while Ultomiris royalties help support spending. Together, the patent extension and expanding clinical programs frame a catalyst path that still depends on Xencor’s ability to advance differentiated assets through complex, costly studies without overextending its balance sheet.

Yet investors should be aware that Xencor’s plan to carry assets into late stage trials without clear out licensing commitments could...

Read the full narrative on Xencor (it's free!)

Xencor's narrative projects $180.3 million revenue and $29.0 million earnings by 2028. This requires 7.1% yearly revenue growth and about a $200 million earnings increase from -$171.1 million today.

Uncover how Xencor's forecasts yield a $28.00 fair value, a 58% upside to its current price.

Exploring Other Perspectives

One member of the Simply Wall St Community currently pegs Xencor’s fair value at US$28 per share, underscoring how tightly clustered some individual expectations can be. Set against Xencor’s reliance on expensive late stage trials with uncertain partnering, this single view highlights why it can be useful to compare several different assessments before forming your own.

Explore another fair value estimate on Xencor - why the stock might be worth as much as 58% more than the current price!

Build Your Own Xencor Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Xencor research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.
• Our free Xencor research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Xencor's overall financial health at a glance.

Looking For Alternative Opportunities?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Uncover the next big thing with financially sound penny stocks that balance risk and reward.
• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com